US Stock MarketDetailed Quotes
OCX OncoCyte
- 2.8200
- +0.0600+2.17%
Close May 21 16:00 ET
37.69MMarket Cap-534P/E (TTM)
2.9800High2.7100Low28.79KVolume2.7100Open2.7600Pre Close81.29KTurnover0.49%Turnover RatioLossP/E (Static)13.36MShares4.864052wk High3.25P/B16.74MFloat Cap2.080052wk Low--Dividend TTM5.94MShs Float204.8000Historical High--Div YieldTTM9.78%Amplitude2.0800Historical Low2.8240Avg Price1Lot Size
OncoCyte Key Stats
Quarterly+Annual
YOY
| (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 53.86%-3.83M | 48.81%-23.33M | 52.72%-4.56M | 80.18%-2.26M | 27.06%-8.2M | 37.49%-8.3M | -26.79%-45.57M | -36.56%-9.65M | -3.76%-11.4M | -39.58%-11.25M |
| Net income from continuing operations | -400.99%-9.13M | 61.89%-27.78M | 64.44%-15.99M | 30.47%-6.49M | -0.40%-8.33M | 129.47%3.03M | -13.74%-72.9M | -25.34%-44.98M | 32.37%-9.33M | 20.90%-8.3M |
| Operating gains losses | ---- | 185.35%1.34M | --61K | --0 | ---- | ---- | 154.08%471K | ---- | ---- | ---- |
| Depreciation and amortization | -29.03%335K | -67.82%1.68M | -74.57%325K | -68.84%426K | -66.40%457K | -61.15%472K | 24.14%5.22M | 2.08%1.28M | 9.80%1.37M | 6.25%1.36M |
| Other non cash items | 119.73%3.31M | 86.32%-4.24M | 180.97%10.94M | 119.12%1.18M | 106.35%423K | -261.07%-16.79M | -213.49%-31.01M | -154.01%-13.51M | -638.09%-6.19M | -8,749.35%-6.66M |
| Change In working capital | 151.86%1.02M | -104.48%-3.97M | -225.31%-510K | 119.38%113K | -1,376.98%-1.61M | -3.86%-1.97M | -1,403.36%-1.94M | -44.32%407K | -165.80%-583K | 148.09%126K |
| -Change in receivables | 190.99%323K | 118.96%109K | 4.55%-21K | 11.70%-166K | -42.19%185K | 116.20%111K | 53.21%-575K | 94.57%-22K | -2,585.71%-188K | 200.63%320K |
| -Change in prepaid assets | -110.02%-62K | 439.39%784K | --0 | 1,357.14%408K | 42.42%-243K | 276.35%619K | -201.76%-231K | -49.31%514K | 104.09%28K | -140.81%-422K |
| -Change in payables and accrued expense | 132.08%854K | -366.37%-4.76M | 60.89%-564K | -31.15%126K | -737.31%-1.66M | -12,576.19%-2.66M | 24.33%-1.02M | -690.98%-1.44M | 122.15%183K | 122.20%260K |
| -Change in other current assets | ---- | ---- | ---- | ---330K | ---- | ---- | ---- | ---- | --0 | --0 |
| -Change in other current liabilities | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -107.77%-15K |
| -Change in other working capital | -190.91%-96K | 7.76%-107K | -104.72%-64K | ---- | ---- | 95.88%-33K | -104.93%-116K | 1,457.00%1.36M | ---656K | ---17K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 53.86%-3.83M | 48.81%-23.33M | 52.72%-4.56M | 80.18%-2.26M | 27.06%-8.2M | 37.49%-8.3M | -26.79%-45.57M | -36.56%-9.65M | -3.76%-11.4M | -39.58%-11.25M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -24K | 110.14%440K | 112.84%103K | 124.91%214K | 111.00%123K | 0 | 68.91%-4.34M | -100.00%-802K | -118.02%-859K | 77.16%-1.12M |
| Net PPE purchase and sale | ---24K | 101.68%73K | 67.08%-264K | 124.91%214K | 111.00%123K | --0 | -93.15%-4.34M | -100.00%-802K | -118.02%-859K | -83.28%-1.12M |
| Net investment purchase and sale | ---- | --367K | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 98.25%-24K | 78.53%-932K | 130.05%241K | -50.87%-1.3M | 233.72%1.5M | 12.11%-1.37M | 68.91%-4.34M | -100.00%-802K | -118.02%-859K | 77.16%-1.12M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 0 | -65.97%12.19M | 70.00%-30K | 94.32%-30K | -66.64%12.27M | 92.11%-28K | -54.31%35.81M | 62.83%-100K | -106.43%-528K | 6,625.59%36.79M |
| Net issuance payments of debt | --0 | 91.81%-117K | 70.00%-30K | 94.32%-30K | 93.03%-29K | 92.73%-28K | 6.84%-1.43M | 64.54%-100K | -26.32%-528K | 0.48%-416K |
| Net common stock issuance | ---- | -57.84%13.85M | --0 | --0 | ---- | ---- | -57.76%32.84M | --0 | --0 | 10,753.25%32.81M |
| Net preferred stock issuance | ---- | -122.93%-1.12M | --0 | --0 | ---- | ---- | --4.88M | --0 | --0 | ---- |
| Net other financing activities | ---- | 11.59%-427K | --0 | --0 | ---- | ---- | 84.24%-483K | --0 | --0 | ---482K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | --0 | -65.97%12.19M | 70.00%-30K | 94.32%-30K | -66.64%12.27M | 92.11%-28K | -54.31%35.81M | 62.83%-100K | -106.43%-528K | 6,625.59%36.79M |
| Net cash flow | ||||||||||
| Beginning cash position | -52.02%11.13M | -37.80%23.2M | -54.13%15.48M | -59.03%19.07M | -38.88%13.5M | -37.80%23.2M | 321.86%37.31M | -25.06%33.75M | -3.46%46.54M | -63.55%22.09M |
| Current changes in cash | 60.27%-3.85M | 14.40%-12.07M | 58.76%-4.35M | 71.95%-3.59M | -77.23%5.57M | 36.24%-9.7M | -149.55%-14.1M | -36.39%-10.55M | -304.27%-12.78M | 297.06%24.45M |
| End cash Position | -46.10%7.28M | -52.02%11.13M | -52.02%11.13M | -54.13%15.48M | -59.03%19.07M | -38.88%13.5M | -37.80%23.2M | -37.80%23.2M | -25.06%33.75M | -3.46%46.54M |
| Free cash flow | 53.57%-3.85M | 52.70%-23.61M | 53.82%-4.83M | 81.43%-2.28M | 33.65%-8.2M | 44.06%-8.3M | -30.69%-49.91M | -39.97%-10.45M | -7.72%-12.26M | -42.65%-12.37M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg